Matches in SemOpenAlex for { <https://semopenalex.org/work/W2776757037> ?p ?o ?g. }
- W2776757037 endingPage "217" @default.
- W2776757037 startingPage "207" @default.
- W2776757037 abstract "Glucagon-like peptide-1 (GLP-1) receptor analogs are a group of therapeutic agents which mimic endogenous GLP-1, exerting their effect by the stimulation of the GLP-1 receptor with a wide distribution. Its activation increases insulin releasing dependent on blood glucose levels, suppression of glucagon secretion and a reduction of hepatic glucose output. It delays gastric emptying and increases satiety. Exenatide is the synthetic version of exendin-4, a natural peptide with similar properties to human GLP-1. There are two pharmaceutical forms, for subcutaneous injection: twice daily and once weekly. Clinical practice guidelines recommend them because of a high efficacy reducing hyperglycemia, low risk of hypoglycemia and a significative weight loss effect. Gastrointestinal adverse events are the most common beside injection site-related. Their cost is the main limitation to use. Areas covered: We review the recent literature investigating the pharmacokinetics and pharmacodynamics and efficacy-safety studies of exenatide twice daily and once weekly in type 2 diabetes Expert opinion: GLP-1 receptor analogs are now positioned as an effective and safe drug for the treatment of type 2 diabetes. Exenatide significally reduces HbA1c and fasting plasma glucose. Additionally, it produces moderate weight loss and decreases blood pressure. One weekly formulation may improve compliance while cost is still a limitation. EXSCEL trial has shown that, despite cardiovascular safety, exenatide do not exhibits cardiovascular benefits." @default.
- W2776757037 created "2018-01-05" @default.
- W2776757037 creator A5061677162 @default.
- W2776757037 creator A5063445538 @default.
- W2776757037 creator A5070481848 @default.
- W2776757037 date "2017-12-28" @default.
- W2776757037 modified "2023-09-24" @default.
- W2776757037 title "Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes" @default.
- W2776757037 cites W1507814807 @default.
- W2776757037 cites W1518543897 @default.
- W2776757037 cites W1902551657 @default.
- W2776757037 cites W1910418518 @default.
- W2776757037 cites W1973333544 @default.
- W2776757037 cites W1976287166 @default.
- W2776757037 cites W1976367840 @default.
- W2776757037 cites W1984740259 @default.
- W2776757037 cites W1985110387 @default.
- W2776757037 cites W1986085856 @default.
- W2776757037 cites W1988939111 @default.
- W2776757037 cites W2001097346 @default.
- W2776757037 cites W2001592873 @default.
- W2776757037 cites W2003444892 @default.
- W2776757037 cites W2008132861 @default.
- W2776757037 cites W2009288620 @default.
- W2776757037 cites W2020787870 @default.
- W2776757037 cites W2021726283 @default.
- W2776757037 cites W2028272916 @default.
- W2776757037 cites W2039296612 @default.
- W2776757037 cites W2043900831 @default.
- W2776757037 cites W2048929025 @default.
- W2776757037 cites W2051493851 @default.
- W2776757037 cites W2054568668 @default.
- W2776757037 cites W2057926043 @default.
- W2776757037 cites W2058239977 @default.
- W2776757037 cites W2058514432 @default.
- W2776757037 cites W2059897529 @default.
- W2776757037 cites W2059979713 @default.
- W2776757037 cites W2061691264 @default.
- W2776757037 cites W2062027317 @default.
- W2776757037 cites W2070710390 @default.
- W2776757037 cites W2072691447 @default.
- W2776757037 cites W2073375369 @default.
- W2776757037 cites W2077969859 @default.
- W2776757037 cites W2078090288 @default.
- W2776757037 cites W2083357334 @default.
- W2776757037 cites W2093738306 @default.
- W2776757037 cites W2098083442 @default.
- W2776757037 cites W2099352903 @default.
- W2776757037 cites W2101613382 @default.
- W2776757037 cites W2103364479 @default.
- W2776757037 cites W2105926302 @default.
- W2776757037 cites W2106758571 @default.
- W2776757037 cites W2107076497 @default.
- W2776757037 cites W2107949845 @default.
- W2776757037 cites W2109517949 @default.
- W2776757037 cites W2115707749 @default.
- W2776757037 cites W2121894019 @default.
- W2776757037 cites W2124977666 @default.
- W2776757037 cites W2128259846 @default.
- W2776757037 cites W2129377335 @default.
- W2776757037 cites W2129934471 @default.
- W2776757037 cites W2133648480 @default.
- W2776757037 cites W2135257149 @default.
- W2776757037 cites W2137805490 @default.
- W2776757037 cites W2139485303 @default.
- W2776757037 cites W2142400535 @default.
- W2776757037 cites W2147817624 @default.
- W2776757037 cites W2150189780 @default.
- W2776757037 cites W2152984355 @default.
- W2776757037 cites W2158778171 @default.
- W2776757037 cites W2159198773 @default.
- W2776757037 cites W2162418500 @default.
- W2776757037 cites W2162934281 @default.
- W2776757037 cites W2167984392 @default.
- W2776757037 cites W2170606300 @default.
- W2776757037 cites W224688689 @default.
- W2776757037 cites W2252243944 @default.
- W2776757037 cites W2257678016 @default.
- W2776757037 cites W2285309079 @default.
- W2776757037 cites W2324536277 @default.
- W2776757037 cites W2519803668 @default.
- W2776757037 cites W2520371120 @default.
- W2776757037 cites W2550011910 @default.
- W2776757037 cites W2588441560 @default.
- W2776757037 cites W2754041380 @default.
- W2776757037 cites W2917198334 @default.
- W2776757037 cites W4211058450 @default.
- W2776757037 cites W573150231 @default.
- W2776757037 doi "https://doi.org/10.1080/17425255.2018.1420160" @default.
- W2776757037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29260924" @default.
- W2776757037 hasPublicationYear "2017" @default.
- W2776757037 type Work @default.
- W2776757037 sameAs 2776757037 @default.
- W2776757037 citedByCount "9" @default.
- W2776757037 countsByYear W27767570372018 @default.
- W2776757037 countsByYear W27767570372019 @default.
- W2776757037 countsByYear W27767570372020 @default.
- W2776757037 countsByYear W27767570372021 @default.